Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/32351
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBallester, Purificación-
dc.contributor.authorEspadas, Cristina-
dc.contributor.authorAlmenara, Susana-
dc.contributor.authorBarrachina, Jordi-
dc.contributor.authorMuriel, Javier-
dc.contributor.authorRamos, Enrique-
dc.contributor.authorToral, Natalia-
dc.contributor.authorBelda, César-
dc.contributor.authorPeiró, Ana-
dc.contributor.otherDepartamentos de la UMH::Farmacología, Pediatría y Química Orgánicaes_ES
dc.date.accessioned2024-06-27T10:37:25Z-
dc.date.available2024-06-27T10:37:25Z-
dc.date.created2023-07-03-
dc.identifier.citationPharmaceuticals 2023, 16, 954es_ES
dc.identifier.urihttps://hdl.handle.net/11000/32351-
dc.description.abstractThe long-term use of psychopharmacology medications in autism spectrum disorder (ASD) hitherto remains controversial due to a lack of evidence about safety and tolerability. In this regard, genotyping the metabolizing enzyme cytochrome P450 (CYP) 2D6, especially its extreme phenotypes, could help to prevent drug-related adverse reactions or adverse events (AEs). There are several medications warranting CYP2D6 screening that are consumed by people with ASD, such as risperidone and aripiprazole to name a few. A naturalistic observational study was carried out in participants with ASD to analyze the influence of the CYP2D6 phenotype in drug tolerability using a local pharmacovigilance system created for this study. In this case, AEs were identified from participants’ electronic health records (EHRs) and paper registries. Other variables were collected: socio-demographic information, comorbidities, and psychopharmacology prescriptions (polypharmacy defined as 4 simultaneous prescriptions) and doses. The genetic analysis included allelic discrimination (CYP2D6*1, *2, *3, *4, *5, *6, *10, *17, and *41) and copy number variations. All of these were used to determine theoretical phenotypes of the metabolic profiles: poor (PM); intermediate (IM); normal (NM); and ultra-rapid (UM). Sex differences were analyzed. A total of 71 participants (30 10 years old, 82% male, 45% CYP2D6 NM phenotype (32 participants)) with a median of 3 (IQR 2–4) comorbidities per person, mainly urinary incontinence (32%) and constipation (22%), were included. CYP2D6 UM showed the highest rate of polypharmacy, whilst, IM participants had the highest rates of neurological and psychiatric AEs, even worse if a CYP2D6 inhibitor drug was prescribed simultaneously. CYP2D6 pharmacogenomics and the monitoring of new antipsychotic prescriptions may make a difference in medication safety in adults with ASD. Particularly in those with psychopharmacology polymedication, it can help with AE avoidance and understanding.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent14es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectautismes_ES
dc.subjectCYP2D6es_ES
dc.subjectpharmacogeneticses_ES
dc.subjectadverse eventses_ES
dc.subjectpolypharmacyes_ES
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::615 - Farmacología. Terapéutica. Toxicología. Radiologíaes_ES
dc.titleCYP2D6 Genotype and Pharmacovigilance Impact on Autism Spectrum Disorder: A Naturalistic Study with Extreme Phenotype Analysises_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.contributor.instituteInstitutos de la UMH::Instituto de Bioingenieríaes_ES
dc.relation.publisherversionhttps://doi.org/10.3390/ph16070954es_ES
Appears in Collections:
Artículos Farmacología, Pediatría y Química Orgánica


Thumbnail

View/Open:
 CYP2D6 Genotype and Pharmacovigilance Impact on Autism Spectrum Disorder. A Naturalistic Study with Extreme Phenotype Analysis.pdf

1,21 MB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???